Skip to main content

Advertisement

Table 2 Number of prescribers for each drug and number of prescribers that received payments

From: Association between industry payments and prescribing costly medications: an observational study using open payments and medicare part D data

S.No. Drug Name Number of prescribers of the druga N Prescribers that received any paymentsb N (%)
1. Lovastatin ER 81 47 (58.02%)
Rosuvastatin 125,058 60,192 (48.13%)
Lovastatin 96,189 42,631 (44.32%)
2 Almotriptan 87 53 (60.92%)
Rizatriptan 224 115 (51.34%)
Sumatriptan 30,940 15,012 (48.53%)
3 Amlodipine+olmesartan 11,018 6687 (60.69%)
Telmisartan 2152 1273 (59.15%)
Irbesartan 35,546 18,308 (51.51%)
4 Ibuprofen+famotidine 116 66 (56.90%)
Celecoxib 75,422 39,328 (52.14%)
Ibuprofen 104,759 41,530 (39.64%)
5 Saxagliptin+metformin 5265 3122 (59.30%)
Sitagliptin 82,593 40,227 (48.71%)
Metformin 168,819 68,718 (40.70%)
6 Naproxen+esomeprazole 787 498 (63.28%)
Celecoxib 75,422 39,328 (52.14%)
Naproxen 79,189 35,057 (44.27%)
  1. aThe number of prescribers in each trio are not mutually exclusive, i.e. same prescriber could prescribe either 1, 2 or all 3 drugs in the trio
  2. bThe number (and percent) of prescribers that received any payment from industry is among the prescribers of the specific drug